Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

Gene Therapy
Anna KanervaAkseli Hemminki

Abstract

In clinical trials with cancer patients, the safety of conditionally replicating adenoviruses (CRAds) has been good. However, marginal data are available on the persistence or antitumor efficacy of these agents. The oncolytic potency of CRAds is determined by their capacity for entering target cells. Consequently, we constructed a retargeted CRAd featuring a secreted marker protein, soluble human carcinoembryogenic antigen (hCEA), which can be measured in growth medium or plasma. We found that virus replication closely correlated with hCEA secretion both in vitro and in vivo. Further, antitumor efficacy and the persistence of the virus could be deduced from plasma hCEA levels. Finally, using in vivo bioluminescence imaging, we were able to detect effective tumor cell killing by the virus, which led to enhanced therapeutic efficacy.

References

Dec 6, 1996·Science·C J Sherr
Sep 3, 1999·Nuclear Medicine and Biology·S S GambhirM E Phelps
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil L Berinstein
May 2, 2002·Nature Medicine·Kah-Whye PengStephen J Russell
May 25, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anna KanervaAkseli Hemminki
Aug 14, 2003·Journal of Virology·Anna SegermanNiklas Arnberg
Aug 30, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anna KanervaAkseli Hemminki
Oct 21, 2003·Nature Medicine·Anuj GaggarAndré Lieber

❮ Previous
Next ❯

Citations

Feb 7, 2009·Cancer Gene Therapy·J J Cody, J T Douglas
Feb 18, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Laura EvginMarianne M Stanford
Jul 29, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anniina KoskiAkseli Hemminki
Jan 20, 2007·Cancer Gene Therapy·J T LamD T Curiel
Nov 22, 2005·Oncogene·J Michael MathisDavid T Curiel
Jan 4, 2008·ILAR Journal·Kurt R ZinnStuart J Frank
Jan 28, 2010·Virology Journal·Jing LiQiana L Matthews
Oct 17, 2006·Current Oncology Reports·Kristopher J KimballRonald D Alvarez
Aug 31, 2007·Expert Opinion on Biological Therapy·Anna KanervaAkseli Hemminki
May 9, 2009·Advanced Drug Delivery Reviews·Kellie S MatthewsDavid T Curiel
Apr 28, 2009·Advanced Drug Delivery Reviews·Dominik E Dorer, Dirk M Nettelbeck
Apr 9, 2016·Oncoimmunology·Jonathan PolLorenzo Galluzzi
Mar 27, 2007·Cancer Letters·Markus J V Vähä-KoskelaAri E Hinkkanen
Dec 7, 2006·Neuroimaging Clinics of North America·Dawid Schellingerhout
Jul 15, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anniina KoskiAkseli Hemminki
Jul 31, 2013·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Aug 7, 2014·Oncoimmunology·Jonathan PolLorenzo Galluzzi
Dec 15, 2010·Gynecologic Oncology·Andreas D HartkopfUlrich Lauer
Jan 6, 2015·Human Gene Therapy·Mari HirvinenVincenzo Cerullo
May 3, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mari RakiAkseli Hemminki
Jul 15, 2015·Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment·Macarena RealNicolás Olea
Sep 14, 2020·Cancer Gene Therapy·Sadia ZafarAkseli Hemminki
Aug 27, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tanja HakkarainenAkseli Hemminki
Mar 23, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kosei HasegawaKah-Whye Peng

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.